Repros CEO resigns; interim CEO named | S&P Global Market Intelligence

Workflow Solutions
Products
See more S&P Global Solutions
See More IHS Markit Solutions
Content
How We Can Help
See More
News & Insights Topics
See More
Featured Events
Webinar ReplaysNew Corporate Realities: Blending Geopolitics, Data, and Digital Transformation
- 07/21/2022
- On-Demand
- 1 Hour
In PersonInteract 2022
- 09/15/2022
- 225 Liberty Street, New York, New York
- 225 Liberty Street
In Person451Nexus
- 10/03/2022
- ARIA Resort and Casino, Las Vegas, Nevada
Platforms
Other Products
- Leveraged Commentary and Data
- Research Online

Repros CEO resigns; interim CEO named

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Global M&A by the Numbers: Q2 2022

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Infographic 2022 Top Tech Trends Shaping Corporations

2 Feb, 2017 | 16:02

Repros CEO resigns; interim CEO named

Author Tayyeba Irum
Theme Healthcare & Pharmaceuticals

Joseph Podolski resigned as president, CEO and board member of Repros Therapeutics Inc. to pursue other interests.

Larry Dillaha, CEO of CavtheRx, has been appointed to serve as interim president and CEO, effective Feb. 2.